The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers.


Authors’ Affiliations: Departments of (1)Preclinical; (2)Medicinal & Protein Chemistry; (3)Medical R&D; (4)New Molecular Entities, Synthon Biopharmaceuticals, Nijmegen, the Netherlands.

Running title: SYD985 is effective in low HER2-expressing breast cancer.

Corresponding Author: Wim Dokter, Synthon Biopharmaceuticals, Microweg 22, 6503 GN Nijmegen, the Netherlands. Tel: +31 (0)24 372 7700, email: Wim.Dokter@Synthon.Com

Disclosure of potential conflict of interest: All authors are employees of Synthon Biopharmaceuticals BV. JL owns stock of Synthon BV.

Financial Support of this study came from Synthon Biopharmaceuticals BV.
ABSTRACT

SYD985 is a HER2-targeting ADC based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin payload. To evaluate the therapeutic potential of this new ADC, mechanistic in vitro studies and in vivo PDX studies were conducted to compare SYD985 head-to-head to T-DM1 (Kadcyla®), another trastuzumab-based ADC. SYD985 and T-DM1 had similar binding-affinities to HER2 and showed similar internalization. In vitro cytotoxicity assays showed similar potencies and efficacies in HER2 3+ cell lines, but in cell lines with low HER2 expression, SYD985 was 3 to 50-fold more potent than T-DM1. In contrast to T-DM1, SYD985 efficiently induced bystander killing in vitro in HER2 negative (HER2 0) cells mixed with HER2 3+, 2+, or 1+ cell lines. At pH conditions relevant for tumors, cathepsin-B cleavage studies showed efficient release of the active toxin by SYD985 but not by T-DM1. These in vitro data suggest that SYD985 might be a more potent ADC in HER2 expressing tumors in vivo, especially in low HER2-expressing and/or in heterogeneous tumors. In line with this, in vivo anti-tumor studies in breast cancer PDX models showed that SYD985 is very active in HER2 3+, 2+, and 1+ models whereas T-DM1 only showed significant anti-tumor activity in HER2 3+ breast cancer PDX models. These properties of SYD985 may enable expansion of the target population to patients who have low HER2 expressing breast cancer, a patient population with still unmet high medical need.
INTRODUCTION

After many years of investigation, antibody-drug-conjugates (ADCs) finally find their way to clinical practice (1). The approval of the CD30-targeting ADC brentuximab-vedotin (marketed as Adcetris®) for treatment of relapsed Hodgkin’s lymphoma and relapsed systemic anaplastic large cell lymphoma (2,3,4) and the more recent approval of ado-trastuzumab emtansine (T-DM1, marketed as Kadcyla®) for the treatment of HER2-positive metastatic breast cancer (5,6,7,8), confirm the potential of ADCs in cancer treatment. The promise of ADCs as a new class of drugs in oncology is further illustrated by the fact that currently over 30 ADCs are in clinical development and many more are in preclinical programs (1).

The approval of T-DM1 was based on studies demonstrating increased progression-free survival and overall survival time of patients with metastatic HER2-positive breast cancer (5,6,7,8) at a dosing regimen (3.6 mg/kg / 3 weeks) that was well tolerated. The introduction of T-DM1 has added great value to the therapeutic armamentarium for patients with HER2-positive metastatic breast cancer; nevertheless, the patient population that might benefit from a HER2-targeting ADC could be expanded by a more effective HER2-targeting ADC. T-DM1 is approved for the treatment of HER2-positive metastatic breast cancers, defined as IHC-HER2 3+ or FISH-positive / IHC-HER2 2+. According to these criteria, approximately 20% to 25% of all metastatic breast cancer patients are currently eligible for T-DM1 therapy (9,10). A HER2-targeting drug that has a clinical benefit in patients whose tumor is FISH-negative but has detectable IHC HER2 expression (2+ and 1+) would at least double that population (10,11).
We recently described SYD985, a new HER2-targeting ADC based on the cleavable linker-duocarmycin payload, valine-citrulline-seco DUocarmycin hydroxyBenzamide Azaindole (vc-seco-DUBA), conjugated to trastuzumab (12). SYD985, and its un-fractionated precursor SYD983, showed high anti-tumor activity in HER2-positive breast cancer patient-derived xenograft (PDX) models in mice (12). To further assess the potential of SYD985, a series of mechanistic in vitro studies and breast cancer PDX studies were initiated to directly compare the anti-tumor activity of SYD985 to T-DM1 in models with different HER2 status. The preclinical profile described in the present paper supports clinical studies with SYD985, particularly studies that aim at extending the target population to patients with metastatic breast cancer tissue that has FISH-negative / IHC-HER2 2+ and 1+ status.

MATERIALS AND METHODS

SYD985 and T-DM1

SYD985 was prepared as described previously (12,13,14,15). Two batches of T-DM1 from Roche (Basel, Switzerland) were obtained, EU batch N0001B02 and US batch 535405. Both batches of T-DM1 showed similar in vitro potency and efficacy data on a panel of four human tumor cell lines (Supplement Figure S1). Head-to-head studies comparing T-DM1 with SYD985 in this paper were conducted with batch N0001B02.

Cancer cell lines and quantification of HER2 levels
Within the period 2011-2014, human tumor cell lines SK-BR-3, UACC-893, NCI-N87, SK-OV-3, MDA-MB-175-VII, ZR-75-1, NCI-H520 and SW-620 were obtained from American Type Culture Collection (Rockville, MD). No further cell-line authentication was conducted. NCI-N87, ZR-75-1, MDA-MB-175-VII, SW-620 and NCI-H520 cells were cultured in RPMI 1640 media (Lonza; Walkersville, MD, USA) supplemented with 10% v/w Fetal Bovine Serum (FBS), which was heat-inactivated (HI) (Gibco-Life Technologies; Carlsbad, CA), at 37°C in a humidified incubator containing 5% CO₂. SK-BR-3 and SK-OV-3 cells were maintained in McCoys 5A medium (Lonza) containing 10% v/w FBS HI, and UACC-893 cells were cultured in DMEM/F-12, Glutamax supplement (Gibco-Life Technologies) containing 20% v/w FBS (Gibco-Life Technologies).

HER2/neu antigen expression on the surface of human tumor cell lines was quantified using the DAKO Qifikit (DAKO, Glostrup, Denmark), according to the manufacturer’s protocol.

Cell viability assays

Cells in complete growth medium were plated in 96-well plates (90 µl/well) and incubated at 37°C, 5% CO₂ at the following cell densities: 6500 SK-BR-3, 10000 UACC-893, 10000 NCI-N87, 2000 SK-OV-3, 2500 MDA-MB-175-VII, 2500 ZR-75-1, 4000 SW-620 and 5000 NCI-H520 cells per well. After an overnight incubation, 10 µl of mAb, drug and/or active toxin (seco-DUBA) were added. Serial dilutions were made in culture medium. For the studies with a shorter exposure of the ADCs, cells were washed once with complete growth medium after 6 and 24 hours, followed by addition of 100 µl of the
same medium. Cell viability was assessed after 6 days, unless indicated otherwise, using the CellTiter-Glo™ (CTG) luminescent assay kit from Promega Corporation (Madison, WI) according to the manufacturer's instructions and as detailed previously (12). Percentage survival was calculated by dividing the measured luminescence for each drug or ADC concentration with the average mean of untreated cells (only growth medium) multiplied by 100.

**Fluorescent labeling of SYD985 and T-DM1.**

SYD985 and T-DM1 were labeled with an Alexa Fluor® 488 reactive dye from Invitrogen, which has a tetrafluorophenyl (TFP) ester moiety that reacts efficiently with primary amines of proteins to form stable dye–protein conjugates. Prior to labeling, T-DM1 or SYD985 were desalted into PBS and the protein concentration was determined using UV absorbance at 280 nm. The pH was adjusted to pH 8.3 and labeling was performed by incubation of T-DM1 or SYD985 solution with an Alexa Fluor 488 solution in DMA in a 9:1 molar ratio (dye:mAb) for 1hr. After incubation, labeled T-DM1 or SYD985 was buffer-exchanged into PBS using gel filtration. The degree of labeling was calculated from the UV absorbance at 280 and 495nm according to the documentation supplied with the labeling kit and was found to be 1.4 for SYD985 and 1.8 for T-DM1.

**Internalization studies.**

Internalization was performed as detailed previously (11). Cells (2,000,000 cells/tube) were incubated for 1 hour at 4°C with 2 ml of 3 μg/ml Alexa Fluor 488 (AF488)-labeled SYD985 or 2 ml of 3 μg/ml Alexa Fluor 488-labeled T-DM1. These cells were split into
two groups after a wash step with ice-cold 1x PBS (Lonza) containing 0.2% v/w BSA (Sigma-Aldrich, St. Louis, MO). For one part of the cells, internalization was assessed upon incubation at 37°C (100 µl cell solution/vial). The other part was used as control cells for the total cell surface binding and was incubated at 4°C. After the indicated incubation times, cells were washed 3-times with ice-cold 1x PBS-0.2% v/w BSA buffer. The remaining surface expression was visualized after quenching with 50 µl of anti-Alexa Fluor 488 Rabbit IgG Ab (1:30 dilution) (Molecular Probes, Life Technologies) for 30 minutes at 4°C. Fluorescence intensities were determined by flow cytometry (BD FACSVers, Fanklin Lakes, NJ) and indicated as the median fluorescence intensity (MFI). Internalization was quantified by calculating the percentage of internalization with the following formula: Median Fluorescence Intensity (MFI) of the “internalized signal (surface AF488-labeled ADC quenched by anti-AF488 and corrected for untreated cells) divided by the total bound AF488-labeled ADC (unquenched cells corrected for untreated cells) multiplied with 100.

**Enzymatic cleavage by Cathepsin B**

0.1 mg/ml of the ADC or 10 µM active toxin (seco-DUBA) was mixed with 5 µg/ml human liver cathepsin B (Calbiochem) in 0.1M Na-acetate buffer pH 5, 6, 6.5 or 7, supplemented with 4 mM DTT. As a control, ADCs or seco-DUBA were diluted in culture medium to a 0.1 mg/ml concentration. After 4 hours of pre-incubation at 37°C, serial dilutions were made from each stock solution in culture medium and 10 µl was added to each well of a 96-wells plate. SW-620 cells (90 µl; 4,000 cells/well) were
cultured with these ADCs or seco-DUBA for 6 days, and the cell viability was measured after 6 days using the CellTiter-Glo™ (CTG) assay kit.

**Bystander killing assay**

HER2-positive SK-BR-3, SK-OV-3, or MDA-MB-175-VII cells were mixed with HER2-negative NCI-H520 cells in McCoy’s 5A medium containing 10% v/w FBS HI. 5,000 cells/well of each cell type (1:1 ratio), or indicated otherwise, were added to a 96-well plates (90 µl/well). Single cultures were seeded at a density of 5,000 cells/well (90 µl/well). After 4 hours, 10 µl of each ADC or seco-DUBA was added. Serial dilutions were made in culture medium. Cell viability was assessed after 6 days, unless indicated otherwise, using the CellTiter-Glo™ (CTG) luminescent assay kit.

**Bystander FACS analyses**

NCI-H520 cells were labeled with CellTrace™ Violet (Life Technologies) according to the manufacturer's instructions. Similar as to the bystander killing studies, a 1:1 ratio of HER2-positive and HER2-negative cells were mixed (10,000 cells/well of each cell type) and plated in 96-well plates (90 µl/well). Single cultures were seeded at a density of 10,000 cells/well (90 µl/well). After an overnight incubation, 10 µl of 1 µg/ml ADC or (seco-pro)drug was added. Cells were detached with 0.1%-trypsin-EDTA after the indicated incubation time and washed with FACS buffer (ice-cold 1x PBS containing 0.2% v/w BSA). Pellet was resuspended in 150 µl FACS buffer supplemented with 0.7 µM TO-PRO®-3 Iodide (Life Technologies). Fluorescence intensities were determined for 1 minute using the high-sensitivity mode on the BD FACSVerse. The CellTrace™
violet labeled NCI-H520 cells allowed detection and gating between the HER2-negative labeled NCH-H520 cells and the HER2-positive non-labeled cells. Dead cells were gated using TO-PRO®-3 iodide. The percentage of gated viable cells was calculated based on the total cell population (viable plus dead cells is 100%).

**Cleavage by CES1c**

A 100 µg/ml concentration of SYD985 was spiked in human K2-EDTA plasma together with 0, 10, 100, 200 and 400 µg/ml recombinant mouse carboxylesterase 1c (CES1c, Cusabio Biotech, Wuhan, China). After 96 hours of incubation at 37°C, plasma samples were snap frozen in liquid nitrogen and stored at -80°C until bioanalysis. SYD985 ADC (conjugated antibody) levels and total antibody (TAb) levels in plasma were quantified using an ELISA based method as described previously (12).

**Cell line and patient-derived xenograft studies**

The *in vivo* anti-tumor activity of SYD985 versus T-DM1 was tested as single dose therapy in the BT-474 cell-line derived xenograft model, and a selection of breast cancer patient-derived xenografts (PDX). The BT-474 model was performed at Oncodesign, Dijon, France. PDX models employed were MAXF 1162, MAXF MX1 and MAXF 449 (Oncotest, Freiburg, Germany), ST313 (South Texas Accelerated Research Therapeutics, San Antonio, Texas, USA), HBCx-34 and HBCx-10 (Xentech, Evry, France). Initial tumor volumes at the day of randomization and treatment ranged from 52-379 mm³. All studies were approved by the local animal care and use committees.
according to established guidelines. The HER2 FISH and IHC status of the BT-474
tumor and tumors from the PDX models as determined by the CROs were
independently confirmed as described below in this materials and methods section. The
characteristics of all tumors used in this paper are summarized in Supplement Table S1.
Representative photographs of the HER2 IHC staining are presented in Supplement
Figure S2. Studies were conducted as detailed previously (12).

**HER2 Gene amplification.**
HER2/neu gene amplification was determined by in situ hybridization (ISH) in formalin-
fixed, paraffin-embedded human breast cancer tissue specimens with a Ventana-Roche
automated platform and an inform HER2 Dual ISH DNA probe cocktail, UltraView SISH
DNP Detection kit, and UltraView Red ISH Dig detection kit, as detailed by the supplier.

**HER2 IHC staining.**
Tissue sections of formalin-fixed paraffin-embedded tumor xenograft samples were
prepared. IHC was performed on the Discovery automated platform (Ventana-Roche)
with the primary Ab anti-HER2/neu (4B5) rabbit monoclonal (Ventana-Roche, ref 790-
4493) and the detection kit OmniMap RB HRP (anti-rabbit multimer, Ventana-Roche
reference 760-4311) associated to the chromogenic kit ChromoMap DAB (Ventana-
Roche reference 760-159, as detailed by the supplier.

**PK studies and bioanalytical assays**
BT-474 tumor bearing female balb/c nu/nu mice and female cynomolgus monkeys were
dosed intravenously with 1, 3 and/or 5 mg/kg SYD985 or T-DM1. Blood samples were
taken at multiple time-points hours after dosing, cooled on ice water and processed to
plasma as soon as possible. Plasma samples were snap frozen in liquid nitrogen and
stored at -80°C until bioanalysis. SYD985 ADC (conjugated antibody) levels and total
antibody (TAb) levels in plasma were quantified using an ELISA based method as
described previously (12). The conjugated antibody assay uses an anti-toxin antibody
as solid phase and a biotinylated anti-idiotype mini antibody for detection. In the TAb
assay, the anti-idiotype mini-antibody is used as solid phase instead of the anti-toxin
antibody. A validated LC-MS/MS based method was used for quantification of active
toxin (DUBA) in plasma. A competitive EIA based method (KTR 756 DM1 ADC EIA kit,
Epitope Diagnostics, San Diego, USA) was used for the determination of T-DM1 levels
in plasma according to the protocol of the supplier.

**Statistical analysis**

Statistical analyses of *in vitro* cytotoxicity assays and *in vivo* xenograft experiments
were performed as detailed previously (12).

**RESULTS**

**SYD985**
SYD985 (Figure 1) was synthesized and prepared as described previously (12). In short, vc-seco-DUBA was coupled to cysteine residues of trastuzumab after partial reduction of the interchain disulfides. SYD985 was further purified by Hydrophobic Interaction Chromatography to deliver a well-defined ADC consisting of predominantly species with a Drug to Antibody Ratio (DAR) of 2 and 4, yielding a mean DAR of 2.8. Some crucial features of the antibody, such as binding affinity and induction of ADCC activity in vitro were not affected by conjugation (data not shown) as was also published for SYD983, the unfractionated form of SYD985 (12).

**Binding and internalization of SYD985 and T-DM1**

Binding capacity and percentage of internalization of SYD985 and T-DM1 were determined in time using flow cytometry analyses in cell lines SK-BR-3 (breast carcinoma), SK-OV-3 (ovarian carcinoma), and MDA-MB-175-VII (breast carcinoma), which are classified as HER2 3+, 2+, and 1+ respectively. SYD985 and T-DM1 showed a similar binding activity (EC50 0.4 - 0.9 µg/ml) to cell surface HER2, irrespective of the HER2 expression level. The rank order of maximum binding capacity of both SYD985 and T-DM1 correlated with the number of HER2 binding sites on the tumor cells. Receptor-mediated endocytosis of Alexa Fluor 488 (AF488)-labeled SYD985 into HER2-positive tumor cells was compared to the uptake of AF488-labeled T-DM1. Fluorescence of each internalized ADC was measured by flow cytometry after quenching of the surface-bound AF488-labeled ADC with an anti-AF488 antibody. A limitation of this approach is the incomplete quenching of the cell-surface bound AF488-
labeled ADCs, as is evident from the 4°C controls. This is in line with the supplier instructions that described a maximum quenching of the AF488 dye up to 90% or lower in the case of conjugated AF488 dye. The kinetics of uptake for SYD985 and T-DM1 were comparable. Also the maximum percentages of internalization for both ADCs are within the same order of magnitude (Figure 2A).

**Cytotoxicity of SYD985 versus T-DM1 *in vitro***

A set of 8 cell lines was selected based on their published HER2-status; breast carcinomas SK-BR-3 and trastuzumab-resistant UACC-893 (both HER2 3+), gastric carcinoma NCI-N87 (HER2 3+), ovarian carcinoma SK-OV-3 (HER2 2+), breast carcinomas MDA-MB-175-VII and ZR-75-1 (both HER2 1+), and metastatic colon carcinoma SW-620 and lung adenocarcinoma NCI-H520 (both HER2 0). The HER2 status of these cell lines was confirmed by Qifi-kit analysis (Supplement Figure S3). We have previously (12) shown that SK-BR-3, SK-OV-3, SW-620, and NCI-H520 all are highly sensitive to the active toxin seco-DUBA, decreasing the cell viability with potencies between 0.08 and 0.4 nM after a 6-day treatment. Cytotoxicity studies in NCI-N87 and UACC-893 cell lines, confirmed high sensitivity to seco-DUBA with potencies of 0.2 nM (Supplement Figure S4A). Since seco-DUBA was less potent against MDA-MB-175-VII (2.5 nM) and ZR-75-1 (8.2 nM) cells at 6 days, we extended the treatment time up to 12 days with corresponding IC50 values of 0.1 and 0.2 nM, respectively (Supplement Figure S4A). As shown in Figure 2B, SYD985 and T-DM1 demonstrate similar potencies in the HER2 3+ cell lines SK-BR-3, UACC-893, and NCI-
N87. IC50 values are 6.9 and 15.7 ng/ml in SK-BR-3, 54.1 and 35.9 ng/ml in UACC-893, and 24.5 and 44.9 ng/ml in NCI-N87, for SYD985 and T-DM1, respectively. Whereas SYD985 and T-DM1 both potently kill UACC-893 cells, we confirmed lack of responsiveness to trastuzumab (Supplement Figure S4B) (16,17). Importantly, SYD985 retained its activity in cell lines with lower HER2 expression, whereas T-DM1 became less potent with IC50 values of 32.4 and 112.1 ng/ml in SK-OV-3, 67.4 and 313.9 ng/ml in MDA-MB-175-VII, and 14.9 and >1000 ng/ml in ZR-75-1, for SYD985 and T-DM1 respectively (see Supplement Table S2 for % efficacy and 95% CI). Neither SYD985 nor T-DM1 was able to kill HER2-negative SW-620 or NCI-H520 cells (Figure 2B), indicating that both ADCs mediate their cytotoxic effect through HER2. Thus, overall these data show that in cell lines with lower HER2 expression (HER2 2+/1+), SYD985 is significantly (factor 3-50) more potent than T-DM1.

Next, we studied the relation between exposure times to ADC and cell killing after 6 days, in three cell lines with different HER2 expression levels. SK-BR-3, SK-OV-3 and MDA-MB-175-VII cells were exposed to SYD985 and T-DM1 for 6 and 24 hours, washed to remove ADCs and cultured until 6 days, except for MDA-MB-175-VII cells (12 days). As control, cells were treated with ADCs during the entire incubation of 6 and 12 days. A short incubation of 6 hr was enough for both SYD985 and T-DM1 to potently kill SK-BR-3 cells after 6 days, indicating that sufficient amounts of the respective toxins were loaded inside cells to induce killing (Figure 2C). For SK-OV-3 and MDA-MB-175-VII cells, in line with their lower HER2 expression, a 6 or even 24 hr exposure to ADC did not induce maximum killing, suggesting that re-cycling of HER2 after internalization...
and re-loading of cells with ADC is needed for potent killing of cells with low HER2 levels (Figure 2C).

**Protease sensitivity and bystander killing in vitro**

Proteases, like cathepsin B, are highly expressed in a wide variety of tumors, including breast cancer tumors, and can also be active extracellularly through secretion by malignant cells (18,19). The sensitivity of SYD985 and T-DM1 to cathepsin B cleavage was evaluated at pH 5 to mimic the acidic milieu in lysosomes and at pH 6, 6.5 and 7 to mimic pH in endosomes and tumor environment. SYD985 and T-DM1 were exposed for 4 hours to activated cathepsin B and release of active toxin was quantified by measuring cytotoxic activity on HER2-negative SW-620 cells. In the absence of cathepsin B, SYD985 did not reduce cell viability of SW-620 cells. However, four hours pre-incubation of SYD985 with cathepsin B, in a pH range between 5 to 7, resulted in potent killing of SW-620 cells, indicating release of active toxin (Figure 3A).

Preincubation of T-DM1 with cathepsin B did not result in cytotoxic activity (Figure 3A), which is in line with the nature of its non-cleavable thioether linker. These data show that SYD985, most likely through its valine-citrulline motif, and in contrast to T-DM1, rapidly releases active toxin through cathepsin B cleavage, an enzyme abundantly present in the tumor cell and microenvironment. In mice, an enzyme present in plasma can cleave vc-seco-DUBA and cause release of active toxin. Adding 1% mouse plasma, causes a dramatic shift in cytotoxic activity of SYD985 on HER2-negative SW620 cells, in contrast to human plasma (Figure 3A). *In vitro* incubation of SYD985 with
recombinant mouse carboxylesterase 1C does release this active species as well (supplement Figure S4B), suggesting that in mouse plasma, carboxylesterase 1C might be responsible for cleavage of vc-seco-DUBA. The position at which this cleavage occurs is most likely the carbamate group connecting the alkylation moiety of the duocarmycin to the linker (Figure 1) since previous studies with valine-citrulline linkers have indicated that this site is quite stable in mouse plasma (20).

Next the ability of SYD985 and T-DM1 to kill HER2-negative bystander tumor cells was explored. NCI-H520 (HER2 0) cells were co-cultured (5000 cells of each cell type per well) with one of the following HER2-positive cell lines, SK-BR-3 (HER2 3+), SK-OV-3 (HER2 2+) or MDA-MB-175-VII (HER2 1+). Cells were treated for 6 days with either SYD985, its non-binding isotype control ADC, T-DM1, or the active toxin seco-DUBA. NCI-H520 cells were insensitive (IC_{50} > 50 nM) to SYD985, its isotype control ADC, and T-DM1 but were sensitive for seco-DUBA (IC_{50} 0.04 nM) (Figure 3B and Supplement Figure S4D). As shown in Figure 3B, treatment of SK-BR-3/NCI-H520 and SK-OV-3/NCI-H520 co-cultures with 1 μg/ml SYD985 resulted in killing of the HER2 0 NCI-H520 cells, whereas the non-binding isotype control ADC and T-DM1 did not. Co-culturing of cells for 6 days resulted in a dissimilar distribution of the % viable HER2-positive and HER2-negative cells, which was indicated by the results of the isotype control ADC and is most likely due to differences in growth rates.

Despite these differences in growth rates, FACS confirmed (Figure 3C) that in the presence of SYD985, HER2 0 cells were killed when co-cultured with SK-BR-3 and SK-OV-3 cells, and not in the presence of T-DM1. Bystander killing in the MDA-MB-175-VII/NCI-H520 co-culture was not so evident after 6 days of incubation, but became
clearly visible after 12 days of incubation (Supplement Figure S5A). To strengthen these bystander killing studies, we determined the minimum proportion of HER2 3+ target cells required for SYD985-mediated bystander killing of HER2 0 cells. Different ratios of HER2-positive SK-BR-3 and HER2-negative NCI-H520 cells were co-cultured, resulting in 100%, 80%, 60%, 40%, 20% and 0% HER2-positive cells (Supplement Figure S5B). With only 20% of HER2 3+ target cells, SYD985 was still able to kill 65% of the mixed cell population indicating bystander killing. In contrast, under the same condition, in which 20% of the HER2 3+ target cells are present, T-DM1 was able to kill 9% of the co-cultured cells (Supplement Figure S5B).

These findings indicate that active toxins are released after processing of SYD985 by HER2 positive cells that are either HER2 3+, 2+, or 1+, resulting in the killing of HER2 0 cells in the immediate vicinity. These results are consistent with previously reported results showing that at least some cleavable linkers could facilitate bystander killing whereas a non-cleavable ADC was not able to kill antigen-negative bystander cells (21,22).

Taken together, this *in vitro* profile indicates that SYD985 might show more anti-tumor potential than T-DM1, especially in tumors that express low levels of HER2 and/or are heterogeneous in their HER2 expression.

**In vivo anti-tumor activity of SYD985 versus T-DM1**

*In vivo* anti-tumor activity of SYD985 *versus* T-DM1 was tested in a cell-line (BT-474) xenograft and a range of breast cancer PDX models, with different HER2 status. After
single dose administration, tumor growth was inhibited in a dose-dependent manner in the BT-474 cell line xenograft model and the MAXF1162 breast cancer PDX model (both HER2 3+; Figure 4 A-B). SYD985 is significantly more active (7 out of 8 mice showed complete tumor remission with SYD985 at 5 mg/kg versus none for T-DM1) than T-DM1 in these models. In contrast to 1 mg/kg T-DM1, 1 mg/kg SYD985 significantly reduced tumor volume compared to the vehicle group in the BT-474 xenograft, and based on the AUCs (tumor volume versus time) of the tumor size data, 5 mg/kg SYD985 is significantly more active (p=0.0148) than 5 mg/kg T-DM1. In MAXF 1162, also a HER2 3+ tumor, there was no statistically significant difference between AUCs of the 10 mg/kg groups at the end of the study (day 72). In FISH negative / IHC HER2 2+ breast cancer PDX models, SYD985 was consistently more active than T-DM1 (Figures 4C-D). The difference was most apparent in the HBCx-34 model (Figure 4D) showing a complete response in 1 out of 8 mice at 3 mg/kg SYD985 and in 4 out of 8 mice when treated with 10 mg/kg. T-DM1 was not active. In the FISH negative / IHC 1+ MAXF 449 model (Figure 4E) SYD985 was dosed in a lower range: 0.3, 1 and 3 mg/kg, and it was observed that 1 and 3 mg/kg SYD985 showed similar efficacy compared to 30 mg/kg T-DM1. Remarkably, in two other FISH negative / IHC HER2 1+ triple negative breast cancer PDX models MAXF-MX1 and HBCx-10, SYD985 appeared to be particularly active (Figure 4F-G). In MAXF-MX1 (Figure 4F) 4 out of 6 mice in the 1 mg/kg group showed a complete response to SYD985, at 3 mg/kg all mice had complete tumor remission. In the HBCx-10 (Figure 4G) 4 out of 7 mice showed a complete response at 1 mg/kg as did all mice in the 3 mg/kg group. In contrast, T-DM1,
even when dosed up to 30 mg/kg, showed no significant anti-tumor activity in these models.

The non-binding isotype control ADC, which is vc-seco-DUBA conjugated to rituximab (prepared with a similar protocol as SYD985 and with similar DAR and HIC profile), showed—at similar dosages—significantly less anti-tumor activity than SYD985 in the HER2 3+ xenograft models (Figure 5 A-B), indicating that the effect of SYD985 is largely HER2-mediated. Like for the BT-474 and MAXF1162, also for both the HER2 2+ PDX models, anti-tumor activity of the non-binding ADC was observed, illustrative of a bystander effect. However, at the lower dosages HER2-mediated effects clearly contributed to the anti-tumor activity of SYD985 (Figure 5C-D). At higher dose (10 mg/kg) this difference between isotype control ADC and SYD985 was no longer apparent in tumor model ST313 (Figure 5C). Finally, also for the three FISH-negative / IHC 1+ models, SYD985-mediated anti-tumor effects could be attributed to be largely due to HER2-mediated effects. Effects induced by the isotype control ADC indicated for non-target mediated anti-tumor activity as well (Figure 5E-G).

In all PDX studies, in all experimental groups, body-weight was determined twice a week as a measure for toxicity and potential overdosing. None of the animals in any of the experimental groups in any of the PDX studies showed significant change in bodyweight.

Taken together, these data show that, in contrast to T-DM1, SYD985 is active in breast cancer PDX models with low (2+ and 1+) HER2 status.
Plasma kinetics

*In vivo* plasma kinetics of SYD985 and T-DM1 were studied in BT-474 tumor bearing mice, since, in contrast to results reported for T-DM1 (23,24), we observe a difference in PK between tumor bearing mice and healthy balb/c mice (12). This is probably caused by target mediated drug disposition, dependent on HER-2 expression levels in the tumor model used, and dependent on the degree of saturation of HER-2 target molecules at the given dose.

As shown in Figure 6A and Supplementary Table S3, SYD985 shows high clearance of conjugated antibody (18.2 – 19.7 ml/h/kg). This is in line with sensitivity of vc-seco-DUBA based ADCs to esterase activity in mouse plasma. This sensitivity for esterases is mouse CES1c-specific, since SYD985 shows high in vitro stability in plasma from CES1c knock-out mice, human and monkey plasma (12). Furthermore, these findings were confirmed in vivo, showing low clearance of conjugated antibody in CES1c knock-out mice (0.51 ml/h/kg, supplementary Figure S6) and monkey (0.52 ml/h/kg).

Remarkably, in monkey conjugated antibody levels were hardly different from total antibody concentrations (clearance of 0.38 ml/h/kg) and T-DM1 concentrations (clearance of 0.64 ml/h/kg) (25), while active toxin (DUBA) plasma levels remain extremely low (Figure 6B). Mean Cmax DUBA level was 0.018 ng/ml versus 5.85 ng/ml for DM1 (25), both dosed at 3 mg/kg ADC in female monkeys.

After T-DM1 administration to mice, ADC clearance is much lower (1.8 – 1.7 ml/h/kg) compared to SYD985 (Figure 6A and supplementary Table S3). This is in line with published PK data for T-DM1 (24) showing a clearance of 0.75 – 0.9 ml/h/kg for T-DM1,
especially when taking into account that the tumor model used shows higher clearance compared to non-tumor bearing mice. Unfortunately, a true quantitative comparison of ADC exposure after dosing of T-DM1 or SYD985 is not possible due to differences between and limitations of the bioanalytical tools. Nevertheless, it is clear that SYD985 shows much higher ADC clearance, most likely due to esterase mediated cleavage of the linker drug, although it cannot be ruled out that other causes of deconjugation, like maleimide exchange to albumin, may contribute. As a consequence, a higher formation of naked antibody is seen for SYD985 compared to T-DM1 in mice.

**Mechanism of anti-tumor activity *in vivo***

To evaluate whether the early release of seco-DUBA in mouse plasma after dosing of SYD985 might affect or contributes to anti-tumor activity we performed a pre-dosing study in the MAXF-MX1 and HBCx-34 PDX models. In both models, a pre-treatment of 24 hours with a high dose of trastuzumab blocked anti-tumor activity of an active dose of SYD985 (Figure 6C-D). These data confirm for these two models the earlier conclusion that HER2-mediated targeting to the tumor is essential for anti-tumor activity. It furthermore proves that anti-tumor activity of SYD985 at least in these two models is not driven by the early release of active toxin in mouse plasma as a result of mouse carboxylesterase cleavage.
DISCUSSION

In order to assess the therapeutic value of SYD985 for treatment of breast cancer patients, we compared its preclinical anti-tumor activity head-to-head to that of T-DM1 in a series of high and low HER2-expressing breast cancer PDX models. In addition, we have performed mechanistic studies *in vitro* comparing SYD985 to T-DM1 for cytotoxic potency, protease sensitivity and bystander induction.

SYD985 and T-DM1 share trastuzumab as the targeting mAb, and indeed binding affinities and internalization of the ADCs on several cell lines *in vitro* was similar. Thus, differences between both ADCs should most likely be attributed to either the linker and/or the toxin. Small differences were evident for the respective *in vitro* cytotoxicity in high expressing HER2 (3+) cell lines, and anti-tumor activity studies *in vivo* in high HER2-expressing breast cancer xenografts. For both ADCs, these data are in line with previous publications (12,26,27,28), although this first head-to-head comparison presented here shows that SYD985, especially *in vivo*, is more active than T-DM1 in high HER2-expressing tumors.

More striking differences were observed in studies in low HER2-expressing cell lines and tumors. SYD985 is a 3- to 50-fold more cytotoxic than T-DM1 in low HER2-expressing (2+ / 1+) cell lines. Similar binding and internalization profiles of SYD985 and T-DM1 do not explain the difference in cytotoxicity potencies. Also, the payload per Ab cannot explain this difference since T-DM1 carries a mean of 3.7 maytansinoid molecules per ADC molecule versus a mean of 2.6 seco-DUBA moieties per molecule SYD985. Apparently, at least for the cell lines tested, cell-permeable duocarmycin seco-
DUBA as released from SYD985 in endosomes and lysosomes is more efficient in cell killing than the maytansinoid payload which becomes available after complete lysosomal degradation of T-DM1 (29,30). The nature of toxicity that both toxins induce is indeed different as the payload of T-DM1 is an anti-mitotic agent preventing microtubule assembly and thereby precluding mitosis in dividing cells (29,30) whereas the toxic payload of SYD985 is a duocarmycin which alkylates DNA resulting in DNA damage, mitochondrial stress, impaired DNA transcription and ultimately cell death in both dividing and non-dividing cells. Potencies of the respective payloads might be different, but this is hard to assess as the free maytansine payload (carrying the lysine-conjugated linker) is cell impermeable and therefore will show an irrelevantly low in vitro cytotoxic activity.

Anti-tumor effects of SYD985 in vivo, also in the low-HER2-expressing PDX models, were largely mediated through HER2, as demonstrated by two independent approaches, i.e. the use of non-binding isotype control ADCs and the blocking experiments where a trastuzumab pretreatment blocked SYD985-mediated anti-tumor activity. Differences in anti-tumor activities became qualitative when SYD985 and T-DM1 were studied for in vivo effects in low HER2-expressing breast cancer PDX models, where SYD985 shows potent anti-tumor activity and T-DM1 is inactive. In vitro data that might contribute to this striking difference in vivo includes sensitivity of the linker in SYD985 for cathepsin B cleavage and potent bystander killing observed for SYD985. T-DM1 contains a non-cleavable linker which depends on complete digestion of the antibody moiety in lysosomes (31). The resulting DM1-containing lysine derivates induce cytotoxicity, however they cannot or poorly diffuse across the plasma membrane.
outside the cell (22) which is in line with lack of bystander killing in our in vitro studies. In SYD985, a cleavable dipeptide valine-citrulline linker is used. Linker cleavage by cysteine proteases, such as cathepsin B, present in early- and late endosomes and lysosomes, results in subsequent release of membrane-permeable active toxin. This enables cell killing of HER2-positive cells but also cell death of neighboring non-antigen expressing cells, in line with results of bystander studies in this paper.

Proteases, like cathepsin B, also reside in the interstitium of tumors. They are highly expressed in a wide variety of tumors, including breast-cancer tumors, and secreted by malignant cells (18,19,32). Extracellular cleavage of vc-seco-DUBA may therefore induce a bystander effect where not only the HER2-targeted tumor cell is killed, but also neighboring cells. This additional mechanism for bystander killing is a possible explanation for the observed difference in anti-tumor activity of SYD985 compared to T-DM1 in low HER2-expressing and/or heterogeneous tumors. These data are in line with a previous publication where efficacy of ADCs with cleavable linkers were shown to be less dependent on target expression than ADCs with non-cleavable linkers (33). This is also illustrated by the observed anti-tumor activity of the non-binding isotype control of SYD985 that indicated that SYD985 mediated anti-tumor activity was not exclusively target mediated.

As was described previously (12), SYD985 shows a poor stability in mouse plasma and consequently poor kinetics in mice leading to a relatively low exposure. We have shown that the poor PK of SYD985 is due to the presence of a mouse-specific carboxylesterase, CES1c, which is not expressed in human or cynomolgus monkey (12,34,35). Currently the exact cleavage site is unconfirmed. Possibly, CES1c
hydrolyzes the carbamate bond connecting the alkylating moiety of the duocarmycin to the linker (Figure 1). CES1c activity and subsequent rapid cleavage of the linker drug in SYD985 leads to early release of active toxin in mouse plasma. In theory, active toxin in plasma in vicinity of the tumor might contribute to anti-tumor activity of SYD985, as mentioned previously (12). Experiments in the present paper showed that a high dose of trastuzumab blocks anti-tumor activity of an active dose of SYD985 in two PDX models. This demonstrates that i) active toxin liberated in plasma or in close vicinity of the tumor does not contribute to anti-tumor activity, and ii) anti-tumor activity of SYD985 is largely HER2-mediated.

The exposure in terms of AUC does drive \textit{in vivo} anti-tumor activity of SYD985 (12) as was also demonstrated for T-DM1 (23,24). The strong anti-tumor activity of SYD985 \textit{in vivo} in mice, is striking, especially if one compares the ADC (conjugated antibody) exposures for both ADCs which is, in mice, approximately 10-fold lower for SYD985 compared to T-DM1. Apart from that, CES1c-mediated release of the toxin in mice is accompanied by a substantial increase in naked mAb, which competes for the same HER2 binding sites and is inactive in these PDX models. Thus, efficacy studies with SYD985 \textit{in vivo} in mice most likely lead to an underestimation of anti-tumor activity in species that will have higher exposure to SYD985, such as human. Monkey PK data and stability studies in human plasma indicate for excellent stability and predictable PK in man (12), thus SYD985 might show an even better efficacy profile in patients. Together, data presented here support the expectation that SYD985 has a clinically relevant efficacy in breast cancer patients who have cancer tissue with low levels of HER2 expression.
ACKNOWLEDGEMENT.

We thank Prof T. Hagemann (London, UK) for providing access to CES1c knockout mice.

REFERENCES


FIGURE LEGENDS

Figure 1. Structure of SYD985.

Figure 2. In vitro profile of SYD985. A) Percentage of internalization in time (0, 1, 4, 21, 45 and 71 hr) for SYD985 and T-DM1 on HER2 3+, 2+ and 1+ tumor cells. B) Cytotoxicity induced by SYD985 (in red) and T-DM1 (in blue) on a panel of 8 human
tumor cell lines with different HER2 levels. C) Cytotoxicity induced after 6 and 24 hours of exposure to SYD985 (in red) and T-DM1 (in blue) on HER2 3+, 2+ and 1+ cells, followed by a wash step and the remaining incubation time.

**Figure 3.** *In vitro* cathepsin B sensitivity, stability in mouse plasma, and bystander killing. A) Cytotoxic activity of released active toxin on HER2-negative SW-620 cells after 4 hours exposure of SYD985 and T-DM1 to cathepsin B, and when SYD985 is exposed to 1% mouse or human plasma supplemented to the culture medium. B) Cytotoxicity induced on HER2-positive, HER2-negative and co-cultured cells after treatment of 6 days with 1 μg/ml of ADCs or 10 nM of active toxin using the CellTiter-Glo luminescence assay. Percentage survival was calculated related to total untreated viable cells. C) Percentage of HER2-positive and HER2-negative gated viable cells in the co-cultured cell population detected by FACS analysis. Dead cells identified by TO-PRO®-3 Iodide were part of the total cell population (is 100%) (bars not shown). NCI-H520 cells were labeled with CellTrace™ Violet allowing detection and gating of each cell type.

**Figure 4.** Antitumor activity of SYD985 compared to T-DM1 in BT-474 xenograft tumor model (A.) and in breast cancer PDX with different levels of HER2 expressions (B-G.). Mice were treated with a single dose administered intravenously as indicated by the arrow on the X-axis (A-G.). Data of isotype control ADC are shown in Figure 5.
**Figure 5.** Antitumor activity of SYD985 compared to isotype control ADC in BT-474 xenograft tumor model (A.) and in breast cancer PDX models with different levels of HER2 expressions (B-G.). Only isotype control ADC data in the BT-474 model were generated in a separate study (A.). All other isotype controls were included within the experiment shown in Figure 4.

**Figure 6.**

A) Mean ADC (SYD985 conjugated antibody or T-DM1 equivalents) plasma concentrations in BT-474 tumor bearing mice after a single intravenous bolus injection of SYD985 or T-DM1 at 1 or 3 mg/kg (dose normalized from 5 mg/kg) (± SEM, n = 3).

B) Mean ADC (SYD985 conjugated antibody), total antibody (TAb) and DUBA plasma concentrations in female cynomolgus monkeys after a single intravenous injection of 3 mg/kg SYD985 (± SEM, n=5).

C) Antitumor activity of SYD985 at 1 mg/kg (MAXF-MX1) or 3 mg/kg (HBCx-34) (D) was blocked by a pre-treatment of 30 or 100 mg/kg trastuzumab, respectively.
Figure 1.
Figure 2.

A.

1. SK-BR-3
   HER2 +

   MDA-MB-175-VII
   (HER2 1+)

   MDAMB-175-VII
   (HER2 2+)

   SK-BR-3
   (HER2 3+)

   AF488-labeled SYD985

2. UACC-893
   HER2 3+

3. NCI-N87
   HER2 3+

4. SK-OV-3
   HER2 2+

   AF488-labeled T-DM1

B.

1. SK-BR-3
   HER2 3+

2. UACC-893
   HER2 3+

3. NCI-N87
   HER2 2+

4. SK-OV-3
   HER2 2+

   MDA-MB-175-VII
   (HER2 1+)

   MDAMB-175-VII
   (HER2 2+)

   SK-BR-3
   (HER2 3+)

   UACC-893
   (HER2 3+)

   NCI-N87
   (HER2 3+)

C.

1. SK-BR-3
   HER2 3+

   ADC - exposure time:
   - T-DM1 - 6h
   - T-DM1 - 24h
   - T-DM1 - 6 days
   - SYD985 - 6h
   - SYD985 - 24h
   - SYD985 - 6 days

2. SK-OV-3
   HER2 2+

   ADC - exposure time:
   - T-DM1 - 6h
   - T-DM1 - 24h
   - T-DM1 - 6 days
   - SYD985 - 6h
   - SYD985 - 24h
   - SYD985 - 6 days

3. MDA-MB-175-VII
   HER2 1+

   ADC - exposure time:
   - T-DM1 - 6h
   - T-DM1 - 24h
   - T-DM1 - 6 days
   - SYD985 - 6h
   - SYD985 - 24h
   - SYD985 - 6 days
**Figure 3.**

**A.**

![Graph](image1)

**B.**

![Graph](image2)

**C.**

![Graph](image3)
Figure 4.

A. BT-474 HER2 3+

B. MAXF 1162 HER2 3+

C. ST313 HP HER2 2+

D. HBCx-34 HP HER2 2+

E. MAXF 449 TNBC HER2 1+

F. MAXF MX1 TNBC HER2 1+

G. HBCx-10 TNBC HER2 1+
Figure 5.

A. BT-474 HER2 3+

B. MAXF 1162 HER2 3+

C. ST313 HP HER2 2+

D. HBCx-34 HP HER2 2+

E. MAXF 449TNBC HER2 1+

F. MAXF MX1 TNBC HER2 1+

G. HBCx-10TNBC HER2 1+
Figure 6.

A. HBCx-34 HP HER2 2+ MAXF MX1 TNBC HER2 1+

B. Time (h)
Concentration (µg/mL)
0 100 200 300 400
0.001 0.01 0.1 1 10 100 T-DM1 1 mg/kg
t Trastuzumab 3 mg/kg
SYD985 3 mg/kg
SYD985 1 mg/kg

C. MAXF MX1 TNBC HER2 1+

D. HBCx-34 HP HER2 2+